Selling shares too soon can be worse than buying poor-performing shares. No matter what happens in markets or the economy, great businesses tend to do well over the long run. It’s almost always a mistake to sell them.
This company was built on the idea of technology “outpacing the law,” and it’s turbocharged a staggeringly effective online network of customers that circumvents traditional business practices in more than 70 countries… And is now generating a profit and shares will soon begin to rise.
This morning, uniQure (Nasdaq: QURE) – which we originally recommended as part of our basket of 10 negative-EV stocks in January with an entry price of $6.62, and recommended again as a standalone pick in October with an entry price of $4.54 – issued a press release announcing that the company has reached an agreement
This quick-serve restaurant has figured out how to beat rising food prices, using a savvy mix of business strategies that have kept its revenue and earnings growing at over 20% per year. It has delivered some of the best returns in the stock market for a decade.
Regardless of what changes an incoming Trump administration might implement, we believe it’s only a matter of time before greed shifts to fear, and prices fall by 50% or more. Those who raise cash now will be in a position to buy world-class businesses at bargain-basement prices.
Covering everything from workers’ compensation to terrorist attacks, the founders of this insurance company are excellent stewards of shareholder capital and they oversee a disciplined and profitable underwriting process, generating high margins and increasing market share.
Nearly a decade ago, Porter made a big gold-stock recommendation that generated massive returns. Now we see another huge opportunity in this space. In fact, this setup could prove to be even better than the last one – because there is one key difference now.
Less than six weeks ago, on Friday, September 6, we recommended buying shares of Sagimet Biosciences (Nasdaq: SGMT). Since we published our report, Sagimet’s management has appeared at several institutional-investor conferences and has also released a fuller data set confirming its blockbuster Phase II clinical trial results for the company’s lead drug candidate denifanstat. Yesterday,
Over my decades in investing, I’ve learned the hard way that recognizing mistakes as quickly as possible, and then acting decisively to fix them – if need be, by trimming or exiting a position – is one of the cardinal attributes that separate professionals from amateurs. And so you can count on me to raise
Global interest-rate cuts have sent share prices toward all-time highs, along with many of the names in The Big Secret on Wall Street portfolio. Our commodities holdings in particular have benefitted from this rate-cutting environment, with the shares of our coal, oil, and mining related companies posting double-digit returns over the last month.